bluebird bio Announces Participation In 27th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will participate in the 27th Annual Piper Jaffray Healthcare conference on Tuesday, December 1st with a fireside chat at 3:00 p.m. ET. The conference is being held at the New York Palace Hotel in New York City.